Dual Path Platform

Chembio’s proprietary DPP® technology differs from classical lateral flow tests by operating in a manner similar to that of the sequential ELISA format which is not sensitive to the “Hook Effect”.

DPP® Technological Advantages:

  • Enhanced multiplex capability up to 8 biomarkers with results in minutes
  • Significantly increased analytical and clinical sensitivity
  • Ability to effectively resolve normal aggregation/agglutination migratory issues, a common concern in lateral flow assays with large particle analytes (e.g., bacteria)
  • Adaptable to multiple sample types such as fingerstick blood, oral fluid, venous whole blood, serum and plasma